ABUS vs CL
Arbutus Biopharma Corp (ABUS) versus Colgate-Palmolive Company (CL) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CL revenue for 2025-12-31 was $20.38B. Net income was $2.13B. Revenue was up 1.4% from 2024-12-31 to 2025-12-31. CL currently screens at market cap $70.88B and trailing P/E 34.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CL currently screens at market cap $70.88B and trailing P/E 34.3.
Not investment advice. Open the ABUS and CL stock pages for the full models.
Not investment advice.